AstraZeneca has announced promising findings from a Phase III trial examining a novel liver cancer regimen. The combination of immunotherapies and targeted approaches, including IMFINZI, IMJUDO, lenvatinib, and transarterial chemoembolization (TACE), demonstrated a significant delay in disease progression.